Literature DB >> 6979361

Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII).

M Silverberg, A P Kaplan.   

Abstract

Pro-Phe-Arg chloromethylketone (PPACMK) at 5.26 microM inactivated the amidolytic activity of native human Hageman factor with an apparent first-order rate constant of 0.75 min-1. The activated forms of Hageman factor, Hfa and HFf, were also inactivated by PPACMK with rate constants 0.82 and 0.72 min-1. These numbers indicate that the activity detectable in native Hageman factor is due to contamination with activated species. Uncleaved Hageman factor reacts slowly with 40 mM diisopropyl fluorophosphate with concomitant loss of its procoagulant activity. Incubation of native Hageman factor with PPACMK does not destroy its procoagulant activity, even in the presence of the activator dextran sulphate, but PPACMK inhibits autoactivation of Hageman factor, suggesting that no active site is formed in uncleaved, surface-bound Hageman factor. The activation of prekallikrein by Hageman factor under initial-rate conditions occurs after a lag and is prevented by an inhibitor of Hageman factor from corn. The kinetics of prekallikrein activation and the effects of inhibitors provide evidence that the amidolytic and proteolytic activities of human Hageman factor reside in the activated forms derived by limited proteolysis of the native molecule.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979361

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 2.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  The autoactivation of factor XII (Hageman factor) induced by low-Mr heparin and dextran sulphate. The effect of the Mr of the activating polyanion.

Authors:  M Silverberg; S V Diehl
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

4.  An analysis of the contact phase of blood coagulation: effects of shear rate and surface are intertwined.

Authors:  K Gregory; D Basmadjian
Journal:  Ann Biomed Eng       Date:  1994 Mar-Apr       Impact factor: 3.934

5.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.

Authors:  B Ghebrehiwet; B P Randazzo; J T Dunn; M Silverberg; A P Kaplan
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

6.  Activation of factor XII-dependent pathways in human plasma by hematin and protoporphyrin.

Authors:  C G Becker; M Wagner; A P Kaplan; M Silverberg; R W Grady; H Liem; U Muller-Eberhard
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Fibrils colocalize caspase-3 with procaspase-3 to foster maturation.

Authors:  Julie A Zorn; Dennis W Wolan; Nicholas J Agard; James A Wells
Journal:  J Biol Chem       Date:  2012-08-07       Impact factor: 5.157

8.  Quantitative characterization of the activation steps of mannan-binding lectin (MBL)-associated serine proteases (MASPs) points to the central role of MASP-1 in the initiation of the complement lectin pathway.

Authors:  Márton Megyeri; Veronika Harmat; Balázs Major; Ádám Végh; Júlia Balczer; Dávid Héja; Katalin Szilágyi; Dániel Datz; Gábor Pál; Péter Závodszky; Péter Gál; József Dobó
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

9.  Anaphylactic release of a prekallikrein activator from human lung in vitro.

Authors:  H L Meier; A P Kaplan; L M Lichtenstein; S Revak; C G Cochrane; H H Newball
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

10.  Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.

Authors:  Yves Decrem; Géraldine Rath; Virginie Blasioli; Philippe Cauchie; Séverine Robert; Jérôme Beaufays; Jean-Marie Frère; Olivier Feron; Jean-Michel Dogné; Chantal Dessy; Luc Vanhamme; Edmond Godfroid
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.